Key Takeaways
- • Sweden's EQT agreed to acquire Qiagen for $10.8 billion, according to GenomeWeb, which will take the company private.
- • The deal, reported on October 21, 2026, marks a take-private transaction by a European private equity firm.
- • The transaction is a significant private equity acquisition in the life sciences sector.
Summary
GenomeWeb reported on October 21, 2026 that Sweden's EQT will buy Qiagen for $10.8 billion, a transaction that will take the company private. The report, written by Madeleine Johnson, was published on the GenomeWeb mergers and acquisitions page.
The source article provides limited additional detail on deal structure, financing, shareholder approvals, or expected closing timing. Readers seeking those terms should consult subsequent coverage and the company's regulatory filings.
The source article provides limited additional detail on deal structure, financing, shareholder approvals, or expected closing timing. Readers seeking those terms should consult subsequent coverage and the company's regulatory filings.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.